FDA announces second approved insulin for use in dogs with diabetes

 According to AAHA NEWStat, the US Food and Drug Administration (FDA) announced recently that it had approved ProZinc for the treatment of hyperglycemia and clinical signs associated with hyperglycemia in dogs with diabetes mellitus (DM). ProZinc (protamine zinc recombinant human insulin) is manufactured by Boehringer Ingelheim Animal Health, Incorporated (BI), and was FDA approved for use in treating feline DM in 2009. While veterinarians have been using ProZinc to treat canine DM for years under extralabel use (see the 2018 AAHA Diabetes Management Guidelines for Dogs and Cats), this marks the first time that the drug has been officially sanctioned by the FDA for treating DM in dogs.